A stem cell CAR-T approach to lasting remission
Original story from Leibniz Institute for Immunotherapy (LIT; Regensburg, Germany).
Purified stem cell memory CAR T-cells achieved complete remissions at ultra-low doses without chemotherapy, demonstrating persistence and fewer side effects than conventional CAR-T therapy.
CAR T-cell therapy has transformed the treatment of hematologic malignancies, yet many patients do not achieve lasting benefit – often because the infused cells fail to expand or persist. This study addresses these challenges by focusing on a more defined cell product: a highly homogeneous population of stem cell memory T (TSCM) cells with strong self-renewal and proliferative capacity. Gattinoni and colleagues previously established a clinical-grade platform for generating CAR-modified TSCM cells, which showed superior anti-leukemic activity in models of acute lymphoblastic leukemia (ALL), providing a rationale for clinical translation.
“Today’s CAR T-cell products are heterogeneous, and that variability is reflected in the range of clinical responses and toxicity profiles we see in patients. To address this, we developed a highly homogeneous CD8+ CAR T-cell product selectively enriched for TSCM cells and compared its performance to conventional CAR T-cells,” explained Gabriele Inchingolo, PhD student in Gattinoni’s team and shared first author of the study.
Top stem cell-based therapies taking the field by storm
Stem cells remain central to regenerative medicine, continuing to offer solutions for repairing damaged tissues, restoring immune function and addressing conditions with innovative approaches.
What the TSCM platform revealed
In this first-in-human trial, the team found that CAR-modified TSCM cells exhibited greater expansion and persistence than standard CAR T-cells, enabling complete responses at low doses even without lymphodepleting chemotherapy, which is typically given before CAR T-cell infusion to help the cells engraft. “The TSCM platform yielded higher CAR T-cell levels on a per cell basis – and across many CAR T-cell studies, high blood CAR T-cell levels have been one of the strongest predictors of clinical efficacy,” confirmed James Kochenderfer, Senior Investigator at the Surgery Branch of the National Cancer Institute (NCI) in Bethesda, USA and co-corresponding author of the study. “Seeing patients achieve complete responses at doses as low as 250,000 cells per kilogram, without chemotherapy preconditioning, validates years of preclinical work and opens a new chapter in CAR T-cell design,” added Professor Luca Gattinoni, Head of the LIT Research Division “Functional Immune Cell Modulation” and first author of the study.
The TSCM platform also demonstrated a favorable tolerability profile. “We also observed less cytokine-release syndrome on this study compared to most other CAR clinical trials that I have participated in,” noted Kochenderfer. Cytokine release syndrome (CRS) is a common and potentially serious inflammatory reaction triggered when CAR T cells become active in the body. Remarkably, even at expansion levels that caused severe CRS in the standard cohort, TSCM-treated patients experienced only mild side effects, suggesting that the TSCM product may separate the beneficial effects of expansion from its toxic consequences.
Beyond clinical outcomes, the study shed light on how the two products behave differently once inside the body. Unlike conventional CAR T-cells, which depleted their stem-like reserves, CAR TSCM cells maintained a durable self-renewing pool throughout the response through clonal succession rather than self-renewal of individual clones. “Rather than differentiating all at once, TSCM cells are recruited in small, sequential waves: each cohort of active clones succeeding the last while preserving the long-term reservoir of quiescent stem-like cells. For the first time, we are witnessing this fundamental biology play out directly in patients,” explained Enrico Lugli, Principal Investigator in the Laboratory of Translational Immunology and Head of Flow Cytometry core facility at Humanitas Research Hospital, Rozzano, Italy and coauthor of the study.
Study design
The phase I trial (NCT01087294), led by James N. Kochenderfer and colleagues at the US National Institutes of Health, enrolled patients with relapsed or refractory CD19+ B-cell malignancies following allogeneic hematopoietic stem cell transplantation (HSCT), a population with severely limited therapeutic options. Patients were treated in two sequential cohorts: one receiving conventional donor-derived CD19 CAR T-cells and the other receiving a TSCM-enriched product. All infusions were administered without lymphodepleting preconditioning, enabling a direct assessment of each product’s intrinsic capabilities.
Immunomonitoring was conducted and coordinated by the LIT researchers, in collaboration with scientists from Humanitas Research Hospital (Milan, Italy), who performed longitudinal patient follow-up using multidimensional flow cytometry and advanced bioinformatics to precisely track the expansion, persistence, and fate of CAR T-cells. As with any early-phase trial, these findings will require validation in larger, randomized cohorts to establish the broader clinical significance of the TSCM approach.
Looking ahead
Where the TSCM product did not succeed, the reasons proved instructive. Treatment failure was driven not by any deficiency in the T cells themselves, but by external factors such as low levels of the target protein on tumor cells, immunosuppressive signals (notably IL-10), and immune responses directed against the CAR construct providing a clear roadmap for the design of next-generation trials.
“We have shown that a more defined, stem-like cell product can perform effectively at lower doses. By employing highly homogeneous TSCM population, we can potentially achieve more consistent engraftment and persistence, paving the way for more predictable outcomes and more rationally designed clinical trials,” concludes Gattinoni.
The full therapeutic potential of CAR-TSCM cells has yet to be realized. Future studies incorporating lymphodepleting preconditioning, fully humanized CAR constructs, and the potential addition of CD4+ T cells are expected to further improve outcomes. The biological principles established here are likely applicable far beyond the post-alloHSCT setting, including autologous CAR T-cell therapies and solid tumors, where limited T-cell persistence has historically been a barrier to efficacy.
This article has been republished from the following materials. Material may have been edited for length and house style. For further information, please contact the cited source. Our press release publishing policy can be accessed here.